Want to see IN:APLLTD full AI Analyst Report?

Alembic Pharmaceuticals Limited (APLLTD) Price & Analysis

2 Followers

APLLTD Stock Chart & Stats

₹930.30

-₹4.90(-0.46%)

At close: Jan 09 4:00 PM EST

₹930.30

-₹4.90(-0.46%)

Day’s Range― - ―

52-Week Range₹635.30 - ₹1,064.70

Previous CloseN/A

Volume60.71K

Average Volume (3M)9.71K

Market Cap

₹161.69B

Enterprise Value₹158.94B

Total Cash (Recent Filing)₹1.55B

Total Debt (Recent Filing)₹14.89B

Price to Earnings (P/E)23.8

Beta1.10

Next Earnings

Jul 31, 2026

EPS Estimate

5.4

Next Dividend Ex-DateN/A

Dividend Yield1.28%

Share Statistics

EPS (TTM)32.24

Shares Outstanding196,563,130

10 Day Avg. Volume3,953

30 Day Avg. Volume9,706

Financial Highlights & Ratios

PEG Ratio1.23

Price to Book (P/B)2.30

Price to Sales (P/S)1.77

P/FCF Ratio50.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)37.72

Revenue Forecast (FY)₹82.09B

Bulls Say, Bears Say

Bulls Say

Conservative Leverage / Strong Balance SheetA low debt-to-equity (~0.25) and expanding shareholders’ equity provide durable financial flexibility. This conservatism supports capex, regulatory compliance spending, and potential M&A without stressing cash flows, reducing refinancing risk during industry cycles and enabling steady long-term investment.

Diversified Business Model (formulations + APIs, Domestic + International)Exposure to both branded generics in India and API/finished-dose sales internationally diversifies revenue drivers and cash sources. The API B2B stream stabilizes utilization and margins, while branded domestic sales give steady cashflow — a structural mix that reduces single-market dependency over months to years.

Steady Revenue Growth And Healthy ROEConsistent top-line growth combined with a ~12% ROE indicates the company can grow sales while generating acceptable returns on capital. That combination supports sustainable reinvestment into manufacturing, pipeline development, and commercial reach, underpinning medium-term earnings resilience.

Bears Say

Volatile Cash Generation / FCF InstabilityWide year-to-year swings in operating cash and free cash flow create execution and working-capital risk. Unpredictable cash conversion can force reliance on external funding for capex or launches, constrain discretionary R&D or dividends, and complicate strategic planning over a 2–6 month horizon and beyond.

Margin Compression Versus Prior PeaksSustained margin pressure relative to peak years suggests structural changes: tougher pricing, product-mix shifts, or higher costs. Lower margins reduce internal funding for growth initiatives, make earnings more sensitive to sales volatility, and limit long-term ability to absorb competitive shocks.

Exposure To Competitive, Approval-driven US Generics MarketReliance on US generic launches and approvals creates lumpy revenue and high execution risk: failures or delays hit sales, while intense competition pressures price and market share. Structurally, this makes near-term revenue and margin outcomes dependent on successful commercialization and timing.

Alembic Pharmaceuticals Limited News

Alembic Pharma Schedules One-on-One Meets With Key Institutional Investors

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has disclosed that its...

17d ago

Alembic Pharmaceuticals Plans One-on-One Meets With Key Institutional Investors

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has scheduled a series...

17d ago

Alembic Pharmaceuticals Lines Up One-on-One Meetings With Key Institutional Investors

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals has scheduled one-on-one investor...

17d ago

Alembic Pharma Sets Virtual AGM, Record Date and Updates Dividend, KYC, and TDS Rules

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals has announced that its 16th Annual...

27d ago

Alembic Pharma Takes 45% Stake in New Canadian Drug Venture

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has shared an announcement. Alembic Pharmaceuticals Limited has signed a shareholders’ agreement...

1M ago

Alembic Pharmaceuticals Announces Death of Senior Delhi-Based Director

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals has announced the death of Mr....

2M ago

Alembic Pharma Wins USFDA Nod for Generic Multiple Sclerosis Drug

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals has received final approval from the...

2M ago

Alembic Pharma Wins USFDA Nod for Methotrexate Injection in Key U.S. Generics Boost

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) just unveiled an announcement. Alembic Pharmaceuticals has received final approval from the...

3M ago

Alembic Pharmaceuticals Forms Thailand Subsidiary to Expand Southeast Asia Footprint

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited has incorporated a...

4M ago

Alembic Pharma Wins USFDA Nod for $500 Million Efinaconazole Generic

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited has received final approval from...

4M ago

APLLTD FAQ

What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?

Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1064.70 in the past 12 months.

What is Alembic Pharmaceuticals Limited’s market cap?

Alembic Pharmaceuticals Limited’s market cap is ₹161.69B.

When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?

Alembic Pharmaceuticals Limited’s upcoming earnings report date is Jul 31, 2026 which is in 25 days.

How were Alembic Pharmaceuticals Limited’s earnings last quarter?

Alembic Pharmaceuticals Limited released its earnings results on May 15, 2026. The company reported ₹11.5 earnings per share for the quarter, beating the consensus estimate of ₹8.655 by ₹2.845.

Is Alembic Pharmaceuticals Limited overvalued?

According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Pharmaceuticals Limited pay dividends?

Alembic Pharmaceuticals Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here

What is Alembic Pharmaceuticals Limited’s EPS estimate?

Alembic Pharmaceuticals Limited’s EPS estimate is 5.4.

How many shares outstanding does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.

What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?

Alembic Pharmaceuticals Limited reported an EPS of ₹11.5 in its last earnings report, beating expectations of ₹8.655. Following the earnings report the stock price went down -0.223%.

Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:APLLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.